Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $21,293 | 9 | 99.3% |
| Food and Beverage | $146.25 | 3 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $21,293 | 9 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $107.61 | 2 | $0 (2017) |
| Neurocrine Biosciences, Inc. | $38.64 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38.64 | 1 | Neurocrine Biosciences, Inc. ($38.64) |
| 2019 | $8,918 | 3 | Gilead Sciences, Inc. ($8,918) |
| 2018 | $9,625 | 4 | Gilead Sciences, Inc. ($9,625) |
| 2017 | $2,858 | 4 | Gilead Sciences Inc ($2,750) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/28/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $38.64 | General |
| Category: Neuropsychiatry | ||||||
| 09/18/2019 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| 03/20/2019 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| 02/25/2019 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,887.50 | General |
| 11/26/2018 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $687.50 | General |
| 09/17/2018 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,712.50 | General |
| 09/17/2018 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| 02/21/2018 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,575.00 | General |
| 12/18/2017 | Gilead Sciences Inc | — | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| 12/18/2017 | Gilead Sciences Inc | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 08/10/2017 | Novartis Pharmaceuticals Corporation | LJN452 (Drug) | Food and Beverage | In-kind items and services | $4.68 | General |
| 08/09/2017 | Novartis Pharmaceuticals Corporation | VAY736 (Drug) | Food and Beverage | In-kind items and services | $102.93 | General |
About Dr. Gary Davis, M.D
Dr. Gary Davis, M.D is a Gastroenterology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265479364.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Davis, M.D has received a total of $21,439 in payments from pharmaceutical and medical device companies, with $38.64 received in 2024. These payments were reported across 12 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($21,293).
Practice Information
- Specialty Gastroenterology
- Other Specialties Hepatology, Transplant Hepatology
- Location Dallas, TX
- Active Since 05/31/2006
- Last Updated 07/03/2014
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1265479364
Products in Payments
- VAY736 (Drug) $102.93
- INGREZZA (Drug) $38.64
- LJN452 (Drug) $4.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Dallas
Dr. Michael Brown, Md, MD
Gastroenterology — Payments: $6.0M
Jay Horton, Md, MD
Gastroenterology — Payments: $419,727
Dr. Lawrence Schiller, Md, MD
Gastroenterology — Payments: $380,832
Dr. Jacqueline O'leary, Md, Mph, MD, MPH
Gastroenterology — Payments: $338,210
Dr. Byron Cryer, M.d, M.D
Gastroenterology — Payments: $331,404
Dr. Sami Arslanlar, Md, MD
Gastroenterology — Payments: $144,674